Processes for reducing the amount of a gaseous iodide-containing impurity present in a recycle gas stream used in the production of ethylene oxide, in particular alkyl iodide and vinyl iodide impurities, are provided. Processes for producing ethylene oxide, ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided.

Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

Processes for reducing the amount of a gaseous iodide-containing impurity present in a recycle gas stream used in the production of ethylene oxide, in particular alkyl iodide and vinyl iodide impurities, are provided. Processes for producing ethylene oxide, ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided.

Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT? bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT? bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

The present invention provides compounds of Formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.

The present invention provides compounds of Formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.

An apparatus and method for continuously producing a cyclic carbonate which are easily scaled up without requiring a large-sized reactor or excessive ancillary facilities even in the case of producing a cyclic carbonate by using an immobilized catalyst as a catalyst on an industrial scale, are able to produce a cyclic carbonate without impairing the expected catalytic efficiency and catalyst lifetime, are economical, and exhibit excellent industrial productivity. The apparatus includes an adiabatic reactor to be filled with a heterogeneous catalyst for reacting an epoxide with carbon dioxide, a circulation path for returning at least a portion of a fluid mixture in a liquid form flowed out through a reactor outlet into the reactor, a carbon dioxide supply means for continuously supplying carbon dioxide in a liquid form or a supercritical state into the circulation path, and an epoxide supply means.

Aromatic entities that modulate HIF-2 activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2 activity are described herein.